Colony in Medical Technology
Navigation Links
Colony in Medical Technology
... broiler chickens were housed in 8' X 8' colony houses. Twenty birds from each colony were identified and infected with a full ... infected birds were reintroduced to their colony after which time ...
... a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...
... a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...
... Immunological effects and clinical outcomes in patients with high-risk melanoma given adjuvant therapy with granulocyte-macrophage colony stimulating factor (GM-CSF, sargramostim) Lead investigator: Lynn Spitler, Northern California Melanoma Center, Saint Mary's Medical ...
... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...
... which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...
... a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...
... a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...
... non patient-specific investigational therapeutics comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and then irradiated for safety. GVAX is designed to be administered through intradermal ...
... in the first Phase 1 clinical trial of CAM- 3001, a fully human monoclonal antibody (MAb) targeting the alpha subunit of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR). The study is designed to evaluate the safety and tolerability of single doses of CAM-3001 in patients with ...
... Infections (E-1616, 12:15 p.m. CDT) -- Comparative Intracellular Activity of 10 Anti-Staphylococcal Antibiotics (AABs) Against a Stable Small colony Variant (SCV) of S. aureus in a Model of Human THP-1 Macrophages (A-1437, 1:15 p.m. CDT) About Oritavancin Oritavancin is a novel ...
... IAPV is a significant marker for CCD." "Unbiased 454 Sequencing technology enabled us to rapidly assemble a comprehensive inventory of microflora in colony Collapse Disorder (CCD) and non-CCD populations, and provided the sequence information needed to identify candidate pathogens," stated Dr. Lipkin. ...
... immunotherapy for prostate cancer is comprised of two prostate cancer cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and irradiated for safety. GVAX cancer immunotherapy for prostate cancer is being developed as a ...
... PCas and can induce cell death of PCas that express functional p53. In this study, we found that roscovitine can inhibit cell growth, reduce colony formation and induce apoptosis in PC3 and PC3-M cells that are p53 negative, when co-cultured with either LY294002 (LY) or Triciribine (also known ...
... symptoms using the CFQ-R questionnaire. Aztreonam lysine for inhalation was also associated with significantly greater reductions in P. aeruginosa colony forming units (a measure of the amount of bacteria present in the lungs) at 28 days compared with placebo. Pseudomonas sensitivity as measured by ...
... immunization strategy uses Rexin-G in combination with Reximmune-C(TM) a tumor-targeted expression vector bearing a granulocyte macrophage colony stimulating factor (GM-CSF) gene. The intent of this two-step approach is to bring a complement of cells involved in humoral and cell-mediated ...
... a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...
... a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...
... Immunological effects and clinical outcomes in patients with high-risk melanoma given adjuvant therapy with granulocyte-macrophage colony stimulating factor (GM-CSF, sargramostim) Lead investigator: Lynn Spitler, Northern California Melanoma Center, Saint Mary's Medical ...
Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...
Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
... 1 clinical trial for the treatment of patients with cancer. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...... which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...
Micromet Expands Committed Equity Financing Facility to $75 Million
... which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...... a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...
IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
... a week for 24 weeks. In addition, some patients in the program were also treated with other agents including aerosol recombinant granulocyte monocyte colony stimulating factor (GM-CSF) an immune stimulating agent (n=20), ifosfamide (n=4), and/or gemcitabine (n=2). Results to date are as follows: -- ...... a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...
Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
... cell) in the blood is too low - is a serious side effect of cancer chemotherapy and can prevent the treatment from being successful. Granulocyte colony stimulating factor (G-CSF) is a human protein that can reverse neutropenia by initiating the production of neutrophils. Recombinant forms of the ...Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
... with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
... Mayo clinic said: "In ex vivo studies, we have seen encouraging preliminary results with Cytopia's compounds including the inhibition of erythroid colony growth from PV patients harboring the JAK2 V617F mutation." Cytopia's Research Director Dr Chris Burns stated: "This data is important validation ...... non patient-specific investigational therapeutics comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and then irradiated for safety. GVAX is designed to be administered through intradermal ...
Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
... on the pharmacokinetic properties of MAXY-G34 and the mobilization of CD34+ stem cells. About MAXY-G34 MAXY-G34 is a novel pegylated granulocyte colony stimulating factor (PEG-GCSF) designed to treat chemotherapy-induced neutropenia. Preclinical and Phase I studies show MAXY-G34 to have novel and ...Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
... including: - Reduction in spleen size of 33 to 100% in five of six patients evaluated - Reduction in erythropoietin-independent colony formation of up to 39% and up to 100% in two patients evaluated -- Relief of constitutional symptoms, including pruritus, fatigue, back ...PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting
... 1990 to 2006 in transfusion-dependent MDS patients (n=578) treated with Epoetin alfa plus or minus granulocyte and granulocyte-macrophage colony stimulating factors (G/GM-CSF) assessed the efficacy of Epoetin alfa in achieving transfusion independence in transfusion-dependent MDS ...... in the first Phase 1 clinical trial of CAM- 3001, a fully human monoclonal antibody (MAb) targeting the alpha subunit of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR). The study is designed to evaluate the safety and tolerability of single doses of CAM-3001 in patients with ...
... Infections (E-1616, 12:15 p.m. CDT) -- Comparative Intracellular Activity of 10 Anti-Staphylococcal Antibiotics (AABs) Against a Stable Small colony Variant (SCV) of S. aureus in a Model of Human THP-1 Macrophages (A-1437, 1:15 p.m. CDT) About Oritavancin Oritavancin is a novel ...
... IAPV is a significant marker for CCD." "Unbiased 454 Sequencing technology enabled us to rapidly assemble a comprehensive inventory of microflora in colony Collapse Disorder (CCD) and non-CCD populations, and provided the sequence information needed to identify candidate pathogens," stated Dr. Lipkin. ...
Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study
... At day 21, the catheters were challenged with an inoculum of one million colony forming units of methicillin-resistant staph aurius (MRSA). The untreated control catheter had 30,000 bacterial colony forming units (CFUs) adhered to the catheter surface while the Ceragenin ...... immunotherapy for prostate cancer is comprised of two prostate cancer cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and irradiated for safety. GVAX cancer immunotherapy for prostate cancer is being developed as a ...
... PCas and can induce cell death of PCas that express functional p53. In this study, we found that roscovitine can inhibit cell growth, reduce colony formation and induce apoptosis in PC3 and PC3-M cells that are p53 negative, when co-cultured with either LY294002 (LY) or Triciribine (also known ...
... symptoms using the CFQ-R questionnaire. Aztreonam lysine for inhalation was also associated with significantly greater reductions in P. aeruginosa colony forming units (a measure of the amount of bacteria present in the lungs) at 28 days compared with placebo. Pseudomonas sensitivity as measured by ...
Telomerase Presentations at the AACR 2007 Annual Meeting
... on telomerase activity in myeloma stem cells. The Johns Hopkins team demonstrated that Geron's telomerase inhibitor, GRN163L, blocked growth and colony formation in both the stem and differentiated subpopulations of myeloma cells. In these studies, no other compounds have been shown to be as active ...... immunization strategy uses Rexin-G in combination with Reximmune-C(TM) a tumor-targeted expression vector bearing a granulocyte macrophage colony stimulating factor (GM-CSF) gene. The intent of this two-step approach is to bring a complement of cells involved in humoral and cell-mediated ...
Other ContentsmaplemastitismarijuanamarijuanamarijuanamastectomymastectomymedialmedialmedialmedialmedialmastoidOther TagsGeneTexBACHEMCALCASalineSalineOrganicsMoticDINDINDINDINDINDINDINDINOther Tagscombating 2combating 3combating 4combating 5combating 6combating 7screen 2screen 3screen 4screen 5screen 6screen 7screen 8screen 9screen 10routine 2routine 3routine 4routine 5routine 6routine 7routine 8routine 9routine 10justify 2justify 3proof 2proof 3proof 4proof 5proof 6proof 7proof 8proof 9proof 10pathogens 2pathogens 3pathogens 4pathogens 5pathogens 6pathogens 7pathogens 8pathogens 9pathogens 10decline 2decline 3decline 4decline 5decline 6decline 7decline 8expectancy 2cargo 2moving 2moving 3moving 4moving 5moving 6moving 7moving 8moving 9moving 10cooperate 2
(Date:11/24/2009)... years it has been prescribed by traditional heale...daches and stomach pain to fever and flu. , Now f...sity have been able to scientifically prove the pa...wise known as Brazilian mint. , Testing this anci...esearcher Graciela Rocha was able to show that whe...
(Date:11/24/2009)...crystallised a protein that may help gut bacteria ...uld be used by probiotic producers to identify str...le. , "Probiotics need to interact with cells lin...ey attach to surfaces in the gut they are more lik...ivity," says Dr Nathalie Juge from the Institute o...
(Date:11/24/2009)... American College of Medical Toxicology (ACMT) hav...ation of the Journal of Medical Toxicology (JMT)...arch 2010. It was previously published by the Uni...f Medical Toxicology , an international, peer-revi...e and practice of medical toxicology. The quarter...
Breaking Biology News(10 mins):Got a pain? -- Have a cup of Brazilian mint 2A sticky solution for identifying effective probiotics 2Springer and the American College of Medical Toxicology to work together 2Employee Benefits Industry Organizes to Protect Flexible Spending Accounts From Elimination or Contribution Limits 54665 1Employee Benefits Industry Organizes to Protect Flexible Spending Accounts From Elimination or Contribution Limits 54665 2Employee Benefits Industry Organizes to Protect Flexible Spending Accounts From Elimination or Contribution Limits 54665 3Hypertronics Circular HyperGrip 28R 29 Connectors Selected for Biosense Websters CARTO 28R 29 3 Navigation System 54663 1Hypertronics Circular HyperGrip 28R 29 Connectors Selected for Biosense Websters CARTO 28R 29 3 Navigation System 54663 2Trust for Americas Health Praises Major Foundations for Supporting Prevention as a Central Part of Health Reform 54661 1Trust for Americas Health Praises Major Foundations for Supporting Prevention as a Central Part of Health Reform 54661 2(Date:11/25/2009)... ,, LittleImprovementShownforthe4thStraigh...ire/-- Today,LungCancerAlliance-Georgia(LCA-GA)is...tisanassessmentofprogressbeingmadeagainstthisletha...CancerAlliance(LCA),theonlynationalorganizationded...plelivingwithoratriskforlungcancer. ,, (Logo: h...
(Date:11/25/2009)... , A drug used to treat colorectal cancer also ca...nsidered first-line therapy for the disease, resea...ort this week. , Mntrier,s disease causes thicken...nausea and vomiting, as well as anemia and swellin...ents are at increased risk for gastric cancer. Pre...
(Date:11/25/2009)... In mice, disks placed under the skin kill tumor ...5 (HealthDay News) -- A cancer vaccine delivered i...mors in mice, a new study reports. , The method...that are loaded with tumor-specific antigens and i...stem to attack tumors. The Harvard University scie...
(Date:11/25/2009)... , Nationwide Imaging Ser...es organizations for diagnostic imaging equipment,...pment, including financing options, service and in.... (dba Atlas Medical Technologies of California) ...er 25, 2009 -- Nationwide Imaging Services is prou...
(Date:11/25/2009)... , BioSpace.com, the prem...ion, unveiled the third edition of the BioForest&t... Englewood, CO (Vocus) November 25, 20...science careers and information, unveiled the thir...this morning., , , , ,This regional campaign is a...
Breaking Medicine News(10 mins):Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2Health News:Nationwide Imaging Services, Inc., Leader In Diagnostic Imaging Equipment, Announces Acquisition Of Kosmic Medical, Inc. (dba Atlas Medical Technologies of California) 2Health News:Nationwide Imaging Services, Inc., Leader In Diagnostic Imaging Equipment, Announces Acquisition Of Kosmic Medical, Inc. (dba Atlas Medical Technologies of California) 3Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2[0] Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer[1] Vanderbilt scientists report first effective medical therapy for rare stomach disorder[2] Implantable Cancer Vaccine Shows Promise[0] Nationwide Imaging Services, Inc., Leader In Diagnostic Imaging Equipment, Announces Acquisition Of Kosmic Medical, Inc. (dba Atlas Medical Technologies of California) [1] BioSpace Showcases Leading Life-Science Companies in the Northwest
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |